A new AHA scientific statement warns that cardiovascular disease is rising fastest among younger women, with stroke rates in ...

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms ...

Joint AASLD/IDSA practice recommendations reflect new data on prevention, treatment, and surveillance of chronic hepatitis B, ...

A peer navigator intervention following a nonfatal opioid overdose in the emergency department does not significantly reduce ...

An interim review finds discrimination, staffing gaps, and poor facilities continue to undermine NHS maternity care in England.

Thirty years after its discovery, scientists are eyeing leptin with renewed interest, for everything from weight loss drug ...

Walk-in appointments can reduce the time to pediatric dermatology visits for both atopic dermatitis and hidradenitis suppurativa and reduce ED visits for atopic dermatitis, a study finds.

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

Shifting the focus from organ to biomarker has unlocked new options for rare and advanced cancers. Uneven efficacy, diagnostic access, and regulation still slow clinical rollout.

Cardiovascular mortality among US adults with obesity tripled from 1999 to 2023, with persistent and widening disparities across certain sociodemographic and geographic groups.